| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FMK | GDSC1000 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | ABT-888 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.6 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.056 | 0.6 |
| mRNA | XMD13-2 | GDSC1000 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | -0.026 | 0.6 |